India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and antibiotic Augmentin.

City brokers expect dividends on GSK shares will keep marching higher. Is the FTSE 100 share a top passive income stock to ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

they can seek approval for a truncated list of uses – the skinny label – that only includes those that are off-patent. The case focuses on GSK's heart drug Coreg (carvedilol), which was ...

Meanwhile, an article in the Financial Times (FT) notes that four drugs discarded by GSK have now reached a combined value of $5 billion, which, the paper says, raises questions about the decision ...

Subsidies and existing MediSave schemes could possibly bring the out-of-pocket cost of Shingrix down to zero, says Health ...

In this process, royalty recipients often face the issue where multiple small future royalty streams cannot fulfill ongoing large lump-sum R&D funding needs. The mismatch is where Royalty Pharma ...

Report with market evolution powered by AI - The global antibiotics market size is estimated to grow by USD 18.22 billion ...

Big pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...